| News

Basel Area remains number one Swiss biotech hotspot

04.02.2025

The Basel Area is maintaining its position as Switzerland's leading biotech location. Last year, around 328 million Swiss francs were invested in biotech companies in the cantons of Basel-Stadt and Basel-Landschaft – significantly more than in any other region. Two of the three largest financing rounds in Switzerland were achieved by startups based at the main campus of Switzerland Innovation Park Basel Area, according to the Swiss Venture Capital Report 2025.

Biotech accounts for 31% of the invested capital per sector (image from Swiss Venture Capital Report 2025)

No other industry in Switzerland receives as much venture capital as the biotech sector. Last year, Swiss biotech startups received around 739 million Swiss francs from investors. This represents an increase of 50 percent over the previous year. The Basel Area has once again proven to be the strongest region in the biotech industry. With 328 million Swiss francs in venture capital, biotech companies in the Basel Area received around 44 percent of the funds invested in the biotech sector in Switzerland.

By far the largest financing round in 2024 was that of Alentis Therapeutics. The biotech start-up, based on the Main Campus of Switzerland Innovation Park Basel Area, received 160 million Swiss francs in a Series D financing round. Bright Peak Therapeutics, also based at the innovation park in Allschwil, secured the third-largest financing round of last year, with 80 million Swiss francs.

Impressive Switzerland Innovation Park Basel Area

The Swiss Venture Capital Report 2025 notes that more and more financing rounds are taking place in the canton of Basel-Landschaft, and they are also getting bigger. The authors attribute this mainly to the existence of Switzerland Innovation Park Basel Area, which is home to numerous biotech startups on the Main Campus and thus favors innovations in the life sciences.

The report lists a total of 20 companies in the Basel Area that have received financing from investors. In addition to Alentis and Bright Peak, these are SixPeaks Bio (27.5 million), Noema Pharma (27 million), BioVersys (12.3 million), Develco Pharma Schweiz (8.6 million), Nouscom (6.3 million), Lyfegen HealthTech (5 million), NXI Therapeutics (3.5 million), Allegria Therapeutics (3.2 million), Axmed (1.8 million) and FimmCy te (1 million). The investment amounts for BioTara, Inofea, KetoSwiss, Myria Biosciences, NeoPrediX, Perseo Pharma, Provuu and Spirecut were not disclosed.

Finally, the Basel Area also saw a number of exits and company acquisitions. MiniNaviDent was acquired by Straumann Group, Chemspeed Technologies was purchased by US firm Bruker, Meteoblue was acquired by Czech company Windy, and was acquired by France’s ProductLife Group.IntiQuan was acquired by France’s ProductLife Group.